Organogenesis Holdings Inc. (NASDAQ:ORGO) Director Sells $127,500.00 in Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now owns 166,879 shares of the company's stock, valued at approximately $851,082.90. The trade was a 13.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Organogenesis Price Performance

ORGO stock traded down $0.03 during trading on Monday, hitting $5.13. 1,215,792 shares of the stock traded hands, compared to its average volume of 1,070,418. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The stock has a market cap of $650.63 million, a price-to-earnings ratio of -85.50 and a beta of 1.66. Organogenesis Holdings Inc. has a one year low of $2.17 and a one year high of $6.71. The company has a 50 day simple moving average of $3.65 and a 200 day simple moving average of $3.35.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised their target price on Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ORGO. Mackenzie Financial Corp raised its stake in Organogenesis by 255.1% during the 4th quarter. Mackenzie Financial Corp now owns 76,353 shares of the company's stock worth $244,000 after buying an additional 54,850 shares during the period. Soleus Capital Management L.P. raised its stake in shares of Organogenesis by 5.4% during the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company's stock worth $39,952,000 after purchasing an additional 645,000 shares in the last quarter. Virtus Investment Advisers Inc. acquired a new stake in Organogenesis in the fourth quarter valued at $157,000. Squarepoint Ops LLC grew its holdings in Organogenesis by 53.2% during the fourth quarter. Squarepoint Ops LLC now owns 126,791 shares of the company's stock worth $406,000 after purchasing an additional 44,051 shares during the period. Finally, Two Sigma Investments LP increased its holdings in shares of Organogenesis by 25.9% during the 4th quarter. Two Sigma Investments LP now owns 382,406 shares of the company's stock worth $1,224,000 after acquiring an additional 78,744 shares during the last quarter. 49.57% of the stock is owned by institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.